{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":4,"sponsored":0,"items":[{"id":"n_2f2k55tqgod7ydyzmlza","seq":862478,"kind":"press_release","title":"CAR T-Cell Therapy Market Forecasts Growth from $7.24B (2026) to $13.78B by 2031, Profiling Bristol-Myers Squibb, Gilead Sciences, Novartis & J&J","url":"https://www.globenewswire.com/news-release/2026/09/30/3371624/28124/en/car-t-cell-therapy-market-forecasts-growth-from-7-24b-2026-to-13-78b-by-2031-profiling-bristol-myers-squibb-gilead-sciences-novartis-j-j.html","summary":"The global CAR T-cell therapy market is projected to grow from USD 7.24 billion in 2026 to USD 13.78 billion by 2031, registering a 13.7% CAGR. Growth is driven by rising cancer prevalence, technological advances, expanding clinical trials, and increased investment, while high costs and adverse effects remain barriers. Yescarta led the product market in 2025, hospitals were the largest end-user segment, and Asia Pacific is forecast to record the fastest growth through 2031.…","published":"2026-09-30T08:47:00Z","seen":"2026-09-30T08:56:58Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business"],"entities":[{"id":"Q266423","name":"Bristol-Myers Squibb","type":"org"},{"id":"Q663596","name":"Gilead Sciences","type":"org"},{"id":"Q507154","name":"Novartis","type":"org"},{"id":"Q333718","name":"Johnson & Johnson","type":"org"}],"story":"st_2f2k55tqgod7ydyzmlza","category":"health","category_p":0.48,"category2":"economy-business","sentiment":"neutral","tone":0.15,"political":0.02},{"id":"n_hmv726gj4e24ig6slffa","seq":628272,"kind":"press_release","title":"Small Molecule Drug Discovery - Global Strategic Business Report Forecasts Growth from $61.5B (2024) to $100B by 2030, Profiling AstraZeneca, Gilead Sciences, Merck & Pfizer","url":"https://www.globenewswire.com/news-release/2026/09/29/3370541/28124/en/small-molecule-drug-discovery-global-strategic-business-report-forecasts-growth-from-61-5b-2024-to-100b-by-2030-profiling-astrazeneca-gilead-sciences-merck-pfizer.html","summary":"AI, computational design and high-throughput screening are accelerating discovery, while targeted therapies, outsourcing and Asia-Pacific expansion create opportunities. AI, computational design and high-throughput screening are accelerating discovery, while targeted therapies, outsourcing and Asia-Pacific expansion create opportunities.","published":"2026-09-29T09:22:00Z","seen":"2026-09-29T09:30:50Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business"],"entities":[{"id":"Q731938","name":"AstraZeneca","type":"org"},{"id":"Q663596","name":"Gilead Sciences","type":"org"},{"id":"Q96472579","name":"Merck","type":"org"},{"id":"Q206921","name":"Pfizer","type":"org"}],"story":"st_hmv726gj4e24ig6slffa","category":"economy-business","category_p":0.72,"sentiment":"neutral","tone":0.27,"political":0.01},{"id":"n_mexbtwarycjdmlfd7nba","seq":550560,"kind":"article","title":"Can Lenacapavir Power Gilead Sciences (GILD)'s Next Growth Phase?","url":"https://www.insidermonkey.com/news/can-lenacapavir-power-gilead-sciences-gilds-next-growth-phase-1845625","published":"2026-09-29T00:43:39Z","seen":"2026-09-29T00:43:39Z","lang":"en","source":{"id":"insidermonkey.com","name":"insidermonkey.com","domain":"insidermonkey.com"},"via":"gdelt-gkg-english","topics":["business","economy","health"],"authors":["Laiba Immad"],"entities":[{"id":"Q663596","name":"Gilead Sciences","type":"org"},{"id":"Q105981469","name":"lenacapavir","type":"other"}],"story":"st_mexbtwarycjdmlfd7nba","category":"science-technology","category_p":0.43,"category2":"economy-business","sentiment":"neutral","tone":0.11,"political":0.02},{"id":"n_meez53kafmin6p6gi7cq","seq":436334,"kind":"article","title":"Critical Comparison: Gilead Sciences (NASDAQ:GILD) vs. Protalix BioTherapeutics (NYSE:PLX)","url":"https://www.dailypolitical.com/2026/09/28/critical-comparison-gilead-sciences-nasdaqgild-vs-protalix-biotherapeutics-nyseplx.html","published":"2026-09-28T13:24:28Z","seen":"2026-09-28T13:24:28Z","lang":"en","source":{"id":"dailypolitical.com","name":"dailypolitical.com","domain":"dailypolitical.com"},"via":"gdelt-gkg-english","topics":["economy","business","health","science"],"authors":["Stacy Sanders"],"entities":[{"id":"Q663596","name":"Gilead Sciences","type":"org"}],"story":"st_meez53kafmin6p6gi7cq","category":"science-technology","category_p":0.29,"category2":"economy-business","sentiment":"neutral","tone":0.24,"political":0.03}]}